Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
European Journal of Nuclear Medicine & Molecular Imaging, 05/04/2012Kobe C et al.
Early and late residual 18F–fluorodeoxyglucose (FDG) uptake, measured using different quantitative SUV parameters, are predictive factors for short–term outcome in patients with advanced non–small–cell lung cancer (NSCLC) treated with erlotinib. Additionally, low residual FDG and 18F–fluorothymidine (FLT) uptake early and late in the course of erlotinib treatment is associated with improved progression–free survival (PFS).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.